Atomo Diagnostics

Atomo Diagnostics FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Atomo Diagnostics (AT1.AX) as of Nov 5, 2026 is 96.86 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 40.09 % — a change of 141.63% (higher).

FCF Conversion

96.86 %

YoY

141.63%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Atomo Diagnostics is 2026 96.86 % . FCF Conversion Rate (FCF/EBITDA) of Atomo Diagnostics was 2025 40.09 % . It decreases by 141.63% higher compared to the previous year.

The Atomo Diagnostics FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2019
52.46 AUD
Jan 1, 2020
89.55 AUD
Jan 1, 2021
168.12 AUD
Jan 1, 2022
89.58 AUD
Jan 1, 2023
62.76 AUD
Jan 1, 2024
68.67 AUD
Jan 1, 2025
40.09 AUD
Jan 1, 2026
96.86 AUD
The Atomo Diagnostics FCF Conversion history
YEARFCF ConversionYoY
96.86 %+141.63%
40.09 %-41.62%
68.67 %+9.42%
62.76 %-29.94%
89.58 %-46.72%
168.12 %+87.73%
89.55 %+70.71%
52.46 %-58.56%
126.59 %+11.18%
113.85 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Atomo Diagnostics Stock analysis

What does Atomo Diagnostics do? Atomo Diagnostics Ltd. generates revenue through the sale of integrated rapid diagnostic test (RDT) devices for blood-based testing, targeting professional and self-testing markets. The company commercializes products like Atomo HIV Self-Test, AtomoRapid HIV (1&2), and ATOMONOW Pregnancy Test, which are supplied under global supply agreements for infectious disease applications including COVID-19, HIV, viral vs bacterial differentiation, and female health. These devices simplify testing procedures with patented technology, offering 15-minute results for HIV screening and blood-based diagnostics. Professional healthcare providers and consumers purchasing self-testing kits form the primary customer segments, with the firm focusing on point-of-care and at-home testing applications. The company’s revenue streams are derived from direct sales of its patented RDT devices, which are designed for both professional use and self-testing. Atomo HIV Self-Test is marketed for HIV screening with results in 15 minutes, while AtomoRapid HIV (1&2) integrates multiple test components into a single device requiring a small blood drop for 15-minute results. These products are sold globally under supply agreements targeting infectious disease diagnostics, including pandemic responses for COVID-19 and ongoing HIV testing needs. The business model emphasizes reliability and usability, appealing to healthcare institutions and individual consumers seeking rapid, accurate diagnostic solutions. Atomo Diagnostics Ltd. focuses on commercializing blood-based RDTs for specific applications, with its products targeting infectious disease testing such as HIV, viral vs bacterial differentiation, and female health. The firm’s supply agreements cover global markets, enabling sales of integrated devices like AtomoRapid HIV (1&2), which consolidates multiple test functions into one platform. Revenue is generated through the sale of these branded devices, with the Atomo HIV Self-Test and ATOMONOW Pregnancy Test serving as key offerings for self-testing segments. Professional healthcare providers and consumers purchasing self-testing kits represent the core customer base driving the company’s revenue model. Atomo Diagnostics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Atomo Diagnostics stock

FCF Conversion Rate (FCF/EBITDA) of Atomo Diagnostics is 96.86 % in 2026.

FCF Conversion Rate (FCF/EBITDA) of Atomo Diagnostics changed from 40.09 % to 96.86 %, representing a 141.63% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Atomo Diagnostics since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Atomo Diagnostics with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Atomo Diagnostics

All Key Metrics — Atomo Diagnostics